ZAVESCA owner Contact Information online
from Actelion Pharmaceuticals Ltd.
ZAVESCA
The mark consists of the word "ZAVESCA" in stylized letters with a series of ellipses.
US serial number:85185312
Application filling date:Nov. 25, 2010
Register:Principal
Mark type:Trademark
Status:Registered. The registration date is used to determine when post-registration maintenance documents are due.
Status date:Jan. 24, 2012
Publication date:Nov. 08, 2011
Standard character claim:No
Mark drawing type:3 - AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/ LETTER(S)/NUMBER(S)
Foreign priority claimed:Yes
Foreign foreign application number:565722010
Foreign foreign application filling date:Jun. 25, 2010
Foreign foreign registration number:604067
Foreign foreign registration date:Aug. 17, 2010
Foreign foreign application registration country:SWITZERLAND
Foreign foreign expiration date:Jun. 25, 2020
Goods and services:For: Pharmaceutical preparations for treating glycolipid storage diseases, including Gaucher's disease and Niemann-Pick type C disease
International Class(es): 005- Primary Class
U.S Class(es): 006,018,044,046,051,052
Class Status: ACTIVE
Basis: 44(e)
Services:Pharmaceutical preparations for treating glycolipid storage diseases
including Gaucher's disease and Niemann-Pick type C disease
Current owner owner name:Actelion Pharmaceuticals Ltd.
Current owner owner address:Gewerbestrasse 16
Allschwil
SWITZERLAND
CH-4123
Current owner legal entity type:CORPORATION
Current owner state or country:SWITZERLAND
Attorney name:Lawrence E. Abelman
Attorney docket number:875179
Correspondent name address:LAWRENCE E. ABELMAN
ABELMAN FRAYNE & SCHWAB
666 3RD AVE
FL 10
NEW YORK,
NEW YORK
UNITED STATES
10017-4046
Correspondent phone:2129499022
Correspondent email:fterranella@lawabel.com
Correspondent fax:2129499190
Correspondent email authorized:Yes
Domestic representative name:Lawrence E. Abelman
Domestic representative phone:2129499022
Domestic representative fax ZAVESCA:2129499190
Latest trademarks
Popular owners
Glaxo Group Limited (173) Novartis AG (130) JOHNSON & JOHNSON (124) Millennium Pharmaceuticals, Inc. (54) Eli Lilly and Company (51) Windmill Health Products, LLC (46) Bayer Aktiengesellschaft (45) SANOFI (41) Wyeth LLC (41) Pfizer Inc. (39) Forest Laboratories, Inc. (34) Bristol-Myers Squibb Company (33) Vital Health Pharmaceuticals, Inc. (31) Primary Investments Group Limited (28) S. C. Johnson & Son, Inc. (28) MERCK SHARP & DOHME CORP. (27) Futurebiotics, LLC (26) MONSTER ENERGY COMPANY (19) Scott Riddell (17) Biocept, Inc. (16)Popular publication dates
Nov. 08, 2011 Mar. 08, 2011 Mar. 15, 2011 Mar. 22, 2011 Nov. 16, 2010 Mar. 29, 2011 Apr. 19, 2011 Apr. 12, 2011 Oct. 19, 2010 Oct. 26, 2010 Apr. 26, 2011 Feb. 15, 2011 Oct. 05, 2010 Oct. 12, 2010 Jan. 25, 2011 Sep. 21, 2010 Jan. 11, 2011 Feb. 22, 2011 Nov. 23, 2010 Sep. 28, 2010Similar brands
